Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Deferred Revenue: 2024

Historic Current Deferred Revenue for Kura Oncology (KURA) over the last 1 years, with Dec 2024 value amounting to $24.3 million.

  • Kura Oncology's Current Deferred Revenue was N/A to $48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.8 million, marking a year-over-year change of. This contributed to the annual value of $24.3 million for FY2024, which is N/A change from last year.
  • Kura Oncology's Current Deferred Revenue amounted to $24.3 million in FY2024.
  • Kura Oncology's 5-year Current Deferred Revenue high stood at $24.3 million for FY2024, and its period low was $24.3 million during FY2024.
  • Its 1-year average for Current Deferred Revenue is $24.3 million, with a median of $24.3 million in 2024.